NCT03786783 2026-04-13
Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
National Cancer Institute (NCI)
Children's Oncology Group
Children's Oncology Group
Dana-Farber Cancer Institute
National Institutes of Health Clinical Center (CC)